Edition:
United States

Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

1.26USD
30 Sep 2016
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.26
Open
$1.25
Day's High
$1.28
Day's Low
$1.25
Volume
24,658
Avg. Vol
132,398
52-wk High
$2.64
52-wk Low
$0.72

Latest Key Developments (Source: Significant Developments)

Frigate Ventures reports 6.9 pct passive stake in Hemispherx Biopharma
Wednesday, 7 Sep 2016 06:35am EDT 

Hemispherx Biopharma Inc :Frigate Ventures Lp reports 6.9 pct passive stake in Hemispherx Biopharma Inc as of August 31, 2016 - SEC filing.  Full Article

Sabby Management LLC reports 6.92 pct passive stake in Hemispherx Biopharma
Thursday, 1 Sep 2016 01:52pm EDT 

Hemispherx Biopharma Inc :Sabby Management LLC reports 6.92 percent passive stake in Hemispherx Biopharma Inc as of August 31 - Sec Filing.  Full Article

Hemispherx says focusing on commercial success by seeking co-development partners
Monday, 15 Aug 2016 05:03pm EDT 

Hemispherx Biopharma Inc : Hemispherx biopharma announces financial results for the six months ended june 30, 2016 .Says now focusing on commercial success by seeking co-development partners.  Full Article

Hemispherx, Avrio strike contract manufacturing deal
Wednesday, 27 Jul 2016 08:30am EDT 

Hemispherx Biopharma Inc : Agreement with Avrio Biopharmaceuticals, Irvine California, to serve as additional contract manufacturer of Hemispherx's Ampligen . Hemispherx Biopharma reaches agreement with Avrio Biopharmaceuticals for the accelerated production of Ampligen .Agreement with Avrio should allow Hemispherx to replenish its Ampligen/Rintatolimod inventory.  Full Article

Hemispherx Biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation
Wednesday, 8 Jun 2016 11:53am EDT 

Hemispherx Biopharma : Hemispherx biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation, resolving disputes with insurance carriers, and obtaining commitments of $3.5 million in payments to company . Two pending disputes in mediation with company insurers have also been settled with a commitment to pay $3,500,000 to company .All four derivative cases have now been settled, subject to final court approval.  Full Article

Hemispherx Biopharma amends and restates agreement with myTomorrows
Monday, 23 May 2016 08:30am EDT 

Hemispherx Biopharma Inc : Hemispherx amends and restates agreement with myTomorrows for the early access program for rintatolimod in Europe . Executed an amended and restated agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows .MyTomorrows will perform EAP activities in Europe, Turkey to include supply of rintatolimod for treatment of chronic fatigue syndrome.  Full Article

Hemispherx Biopharma qtrly loss per share $0.01
Monday, 16 May 2016 05:09pm EDT 

Hemispherx Biopharma Inc : Hemispherx biopharma announces financial results for the three months ended march 31, 2016 .Quarterly loss per share $0.01.  Full Article

Hemispherx Biopharma Inc receives European patent office grant of new composition of matter patent covering ampligen formulations
Monday, 28 Sep 2015 08:30am EDT 

Hemispherx Biopharma Inc:Says that it received formal notice on Sept. 21, that European Patent Office's Examining Division granted the company's application titled " Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity ".  Full Article

Hemispherx Biopharma appoints new president
Thursday, 13 Aug 2015 08:30am EDT 

Hemispherx Biopharma, Inc:Announced that the Board has appointed Thomas Equels as the new President.  Full Article

Hemispherx Biopharma Inc expands its collaboration With Emerge Health
Tuesday, 11 Aug 2015 08:30am EDT 

Hemispherx Biopharma Inc:Has executed an agreement with Emerge Health Pty Ltd. (Emerge).To seek approval of Alferon N Injection in Australia and New Zealand and to commence distribution of Alferon in both countries on a named-patient basis, where deemed appropriate.Will collaborate on seeking regulatory approval from Australia's Therapeutic Goods Administration (TGA) and New Zealand's Medicines and Medical Devices Safety Authority.Under an exclusive license to sell, market, and distribute Alferon N Injection in Australia and New Zealand, Emerge will implement regulatory-compliant programs to educate physicians about Alferon.Hemispherx will support these efforts and will supply Alferon at predetermined transfer price.  Full Article

BRIEF-Frigate Ventures reports 6.9 pct passive stake in Hemispherx Biopharma

* Frigate Ventures Lp reports 6.9 pct passive stake in Hemispherx Biopharma Inc as of August 31, 2016 - SEC filing Source text: (http://bit.ly/2cATyOR) Further company coverage: